Drug Trial Radar · NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 9, 2025
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
SHR2554; SHR-A2102Drug
SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days
SHR2554; AdabelimumabDrug
SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days
SHR2554; SHR-1701Drug
SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: 21days after the first administration of each subject
- AETime frame: from Day1 to 30 days after last dose
- Incidence and severity of serious adverse events (SAE)Time frame: from Day1 to 30 days after last dose
- ORRTime frame: from first dose to disease progression or death, whichever comes first, up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.